Millennium Management LLC Buys 288,259 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF)

Millennium Management LLC raised its stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) by 188.8% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 440,944 shares of the company’s stock after purchasing an additional 288,259 shares during the period. Millennium Management LLC owned 0.86% of Cardiff Oncology worth $1,914,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Acorn Capital Advisors LLC bought a new position in Cardiff Oncology in the 4th quarter worth $6,260,000. Adage Capital Partners GP L.L.C. purchased a new position in shares of Cardiff Oncology in the fourth quarter valued at about $5,609,000. Laurion Capital Management LP purchased a new position in shares of Cardiff Oncology in the fourth quarter valued at about $2,504,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of Cardiff Oncology in the fourth quarter valued at about $607,000. Finally, Boothbay Fund Management LLC purchased a new position in shares of Cardiff Oncology in the fourth quarter valued at about $564,000. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Stock Performance

CRDF opened at $3.35 on Tuesday. The stock has a market cap of $222.86 million, a price-to-earnings ratio of -3.56 and a beta of 1.81. The stock’s 50 day moving average price is $2.86 and its 200-day moving average price is $3.45. Cardiff Oncology, Inc. has a one year low of $2.01 and a one year high of $5.64.

Cardiff Oncology (NASDAQ:CRDF) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The firm had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.09 million. Cardiff Oncology had a negative net margin of 6,238.17% and a negative return on equity of 73.97%. As a group, analysts predict that Cardiff Oncology, Inc. will post -0.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright boosted their price objective on Cardiff Oncology from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, May 9th.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.